{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:24:37Z","timestamp":1773527077659,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,11]]},"DOI":"10.7759\/cureus.24920","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T21:27:10Z","timestamp":1652304430000},"source":"Crossref","is-referenced-by-count":7,"title":["Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Maurice H","family":"Dick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arowa","family":"Abdelgadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishnavi Vijaya","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamna","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abanti","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Data & statistics on sickle cell disease [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. (2020). Accessed. September 18th, 2021: https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe","volume":"102","author":"Maitra P","year":"2017","unstructured":"Maitra P, Caughey M, Robinson L, et al.. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica. 2017, 102:626-36. 10.3324\/haematol.2016.153791","journal-title":"Haematologica"},{"key":"ref3","article-title":"Bone Marrow Transplantation In Sickle Cell Disease","author":"Ashorobi D","year":"2021","unstructured":"Ashorobi D, Bhatt R. Bone Marrow Transplantation In Sickle Cell Disease. StatPearls, Treasure Island, FL; 2021."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne AB","year":"2020","unstructured":"Payne AB, Mehal JM, Chapman C, Haberling DL, Richardson LC, Bean CJ, Hooper WC. Trends in sickle cell disease-related mortality in the United States, 1979 to 2017. Ann Emerg Med. 2020, 76:S28-36. 10.1016\/j.annemergmed.2020.08.009","journal-title":"Ann Emerg Med"},{"key":"ref5","unstructured":"American Society of Hematology. Longevity for those with sickle cell disease linked to care maintenance and family involvement. (2016). Accessed. May 10, 2022: http:\/\/2016202118."},{"key":"ref6","unstructured":"Faststats - life expectancy [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. (2021). Accessed. September 18th, 2021: https:\/\/www.cdc.gov\/nchs\/fastats\/life-expectancy.htm."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16314","article-title":"Sudden death in sickle cell disease: current experience","volume":"188","author":"Nze C","year":"2020","unstructured":"Nze C, Fortin B, Freedman R, Mandell E, Puligandla M, Neuberg D, Achebe M. Sudden death in sickle cell disease: current experience. Br J Haematol. 2020, 188:e43-5. 10.1111\/bjh.16314","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.865.865","article-title":"Mortality trends and causes of death in persons with sickle cell disease in the United States, 1979-2014","volume":"130","author":"Payne AB","year":"2017","unstructured":"Payne AB, Mehal JM, Chapman C, Haberling DL, Richardson LC, Bean CJ, Hooper WC. Mortality trends and causes of death in persons with sickle cell disease in the United States, 1979-2014. Blood. 2017, 130:865. 10.1182\/blood.V130.Suppl_1.865.865","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management","volume":"105","author":"Darbari DS","year":"2020","unstructured":"Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. Eur J Haematol. 2020, 105:237-46. 10.1111\/ejh.13430","journal-title":"Eur J Haematol"},{"key":"ref10","unstructured":"Accessdata.fda.gov- US food and drug administration, Endari. (2020). Accessed. September 21st, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208587s003lbl.pdf."},{"key":"ref11","unstructured":"Accessdata.fda.gov- US food and drug administration, OXBRYTA. (2019). Accessed. September 21st, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213137s000lbl.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199603020-00003","article-title":"Molecular basis of sickle cell-endothelial cell interactions","volume":"3","author":"Wick TM","year":"1996","unstructured":"Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol. 1996, 3:118-24. 10.1097\/00062752-199603020-00003","journal-title":"Curr Opin Hematol"},{"key":"ref13","unstructured":"FDA approves crizanlizumab-tmca for sickle cell disease. (2019). Accessed. September 21st, 2021: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizanlizumab-tmca-sickle-cell-disease."},{"key":"ref14","unstructured":"Accessdata.fda.gov- US food and drug administration, ADAKVEO. (2021). Accessed. September 21st, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761128s000lbl.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17312","article-title":"Sickle cell disease: progress towards combination drug therapy","volume":"194","author":"Pace BS","year":"2021","unstructured":"Pace BS, Starlard-Davenport A, Kutlar A. Sickle cell disease: progress towards combination drug therapy. Br J Haematol. 2021, 194:240-51. 10.1111\/bjh.17312","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00435","article-title":"Recent advances in the treatment of sickle cell disease","volume":"11","author":"Salinas Cisneros G","year":"2020","unstructured":"Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol. 2020, 11:435. 10.3389\/fphys.2020.00435","journal-title":"Front Physiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Aromataris E, Munn Z. JBI Manual for Evidence Synthesis. (2020). Accessed. May 10, 2022: http:\/\/Aromataris E, Munn Z.","DOI":"10.46658\/JBIMES-20-01"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier J","year":"2015","unstructured":"Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015, 3:e00149. 10.1002\/prp2.149","journal-title":"Pharmacol Res Perspect"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou TC","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006, 58:621-81. 10.1124\/pr.58.3.10","journal-title":"Pharmacol Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1039\/c0ib00130a","article-title":"The mass-action law based algorithms for quantitative econo-green bio-research","volume":"3","author":"Chou TC","year":"2011","unstructured":"Chou TC. The mass-action law based algorithms for quantitative econo-green bio-research. Integr Biol (Camb). 2011, 3:548-59. 10.1039\/c0ib00130a","journal-title":"Integr Biol (Camb)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106546","article-title":"A reanalysis of pain crises data from the pivotal l-glutamine in sickle cell disease trial","volume":"110","author":"Zaidi AU","year":"2021","unstructured":"Zaidi AU, Estepp J, Shah N, Alkindi S, Ezzat H, Lam H, Minniti CP. A reanalysis of pain crises data from the pivotal l-glutamine in sickle cell disease trial. Contemp Clin Trials. 2021, 110:106546. 10.1016\/j.cct.2021.106546","journal-title":"Contemp Clin Trials"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara Y","year":"2018","unstructured":"Niihara Y, Miller ST, Kanter J, et al.. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018, 379:226-35. 10.1056\/NEJMoa1715971","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212","article-title":"A Phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky E","year":"2019","unstructured":"Vichinsky E, Hoppe CC, Ataga KI, et al.. A Phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019, 381:509-19. 10.1056\/NEJMoa1903212","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868893","article-title":"A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease","volume":"133","author":"Howard J","year":"2019","unstructured":"Howard J, Hemmaway CJ, Telfer P, et al.. A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 2019, 133:1865-75. 10.1182\/blood-2018-08-868893","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13896","article-title":"Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease","volume":"85","author":"Hutchaleelaha A","year":"2019","unstructured":"Hutchaleelaha A, Patel M, Washington C, et al.. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. Br J Clin Pharmacol. 2019, 85:1290-302. 10.1111\/bcp.13896","journal-title":"Br J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga KI","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J, et al.. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017, 376:429-39. 10.1056\/NEJMoa1611770","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25139","article-title":"Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access","author":"Blyden G","year":"2018","unstructured":"Blyden G, Bridges KR, Bronte L. Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access. Am J Hematol. 2018, 10.1002\/ajh.25139","journal-title":"Am J Hematol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26342","article-title":"First case of DRESS (drug reaction with eosinophilia and systemic symptoms) associated with voxelotor","volume":"96","author":"Lee M","year":"2021","unstructured":"Lee M, Stringer T, Jacob J, Friedman EM, Minniti C, Billett HH, Curtis SA. First case of DRESS (drug reaction with eosinophilia and systemic symptoms) associated with voxelotor. Am J Hematol. 2021, 96:E436-9. 10.1002\/ajh.26342","journal-title":"Am J Hematol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26002","article-title":"Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease","volume":"95","author":"Karkoska K","year":"2020","unstructured":"Karkoska K, Quinn CT, Clapp K, McGann PT. Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease. Am J Hematol. 2020, 95:E338-9. 10.1002\/ajh.26002","journal-title":"Am J Hematol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16068","article-title":"Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion","volume":"60","author":"Ershler WB","year":"2020","unstructured":"Ershler WB, Holbrook ME. Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion. Transfusion. 2020, 60:3066-7. 10.1111\/trf.16068","journal-title":"Transfusion"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25389","article-title":"Voxelotor treatment of a patient with sickle cell disease and very severe anemia","volume":"94","author":"Shet AS","year":"2019","unstructured":"Shet AS, Mendelsohn L, Harper J, et al.. Voxelotor treatment of a patient with sickle cell disease and very severe anemia. Am J Hematol. 2019, 94:E88-90. 10.1002\/ajh.25389","journal-title":"Am J Hematol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2018.7643","article-title":"Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease","volume":"10","author":"Telfer P","year":"2018","unstructured":"Telfer P, Agodoa I, Fox KM, et al.. Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease. Hematol Rep. 2018, 10:7643. 10.4081\/hr.2018.7643","journal-title":"Hematol Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2020.08.008","article-title":"Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials","volume":"92","author":"Ali MA","year":"2020","unstructured":"Ali MA, Ahmad A, Chaudry H, Aiman W, Aamir S, Anwar MY, Khan A. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020, 92:11-18.e1. 10.1016\/j.exphem.2020.08.008","journal-title":"Exp Hematol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25742","article-title":"Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy","volume":"95","author":"Roumenina LT","year":"2020","unstructured":"Roumenina LT, Chadebech P, Bodivit G, et al.. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol. 2020, 95:456-64. 10.1002\/ajh.25742","journal-title":"Am J Hematol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4410","article-title":"Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study","volume":"2","author":"Sinha CB","year":"2019","unstructured":"Sinha CB, Bakshi N, Ross D, Krishnamurti L. Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study. JAMA Netw Open. 2019, 2:e194410. 10.1001\/jamanetworkopen.2019.4410","journal-title":"JAMA Netw Open"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4384","article-title":"Voxelotor modulates the analgesic effect of certain opioids","volume":"13","author":"Ballas SK","year":"2021","unstructured":"Ballas SK. Voxelotor modulates the analgesic effect of certain opioids. J Clin Med Res. 2021, 13:130-2. 10.14740\/jocmr4384","journal-title":"J Clin Med Res"},{"key":"ref39","article-title":"Drugs and Lactation Database, Voxelotor","author":"Bethesda (MD)","year":"2006","unstructured":"Bethesda (MD). Drugs and Lactation Database, Voxelotor. National Library of Medicine (US) (LactMed) [Internet]. . 2006,","journal-title":"National Library of Medicine (US) (LactMed) [Internet]."},{"key":"ref40","unstructured":"Drugs.com. Voxelotor side effects. (2021). Accessed. September 28th, 2021: https:\/\/www.drugs.com\/sfx\/voxelotor-side-effects.html."},{"key":"ref41","unstructured":"RxList. ADAKVEO. (2021). Accessed. September 28th, 2021: https:\/\/www.rxlist.com\/adakveo-drug.htm#description."},{"key":"ref42","unstructured":"Medscape. crizanlizumab (Rx). Accessed. September 28th, 2021: https:\/\/reference.medscape.com\/drug\/adakveo-crizanlizumab-4000004."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90507-comparing-the-safety-and-efficacy-of-l-glutamine-voxelotor-and-crizanlizumab-for-reducing-the-frequency-of-vaso-occlusive-crisis-in-sickle-cell-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:08Z","timestamp":1707507608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90507-comparing-the-safety-and-efficacy-of-l-glutamine-voxelotor-and-crizanlizumab-for-reducing-the-frequency-of-vaso-occlusive-crisis-in-sickle-cell-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.24920","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}